Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 67,885 Shares

Posted by Donald Scott on May 13th, 2026

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) Director Luke Evnin sold 67,885 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $0.64, for a total transaction of $43,446.40. Following the sale, the director directly owned 1,171,175 shares of the company’s stock, valued at $749,552. This trade represents a 5.48% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

On Monday, May 11th, Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total transaction of $22,745.16.
On Friday, May 8th, Luke Evnin sold 305,741 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.70, for a total value of $214,018.70.
On Thursday, May 7th, Luke Evnin sold 79,086 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total transaction of $49,824.18.
On Wednesday, May 6th, Luke Evnin sold 14,635 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.66, for a total transaction of $9,659.10.
On Tuesday, May 5th, Luke Evnin sold 6,860 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.69, for a total value of $4,733.40.
On Monday, May 4th, Luke Evnin sold 47,963 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.72, for a total value of $34,533.36.
On Friday, May 1st, Luke Evnin sold 58,394 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.73, for a total transaction of $42,627.62.
On Thursday, April 30th, Luke Evnin sold 168,262 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.72, for a total transaction of $121,148.64.
On Wednesday, April 29th, Luke Evnin sold 56,559 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total value of $39,025.71.
On Tuesday, April 28th, Luke Evnin sold 95,412 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.73, for a total value of $69,650.76.

Werewolf Therapeutics Price Performance

Shares of HOWL opened at $0.63 on Wednesday. The stock has a market capitalization of $30.72 million, a price-to-earnings ratio of -0.51 and a beta of 0.41. Werewolf Therapeutics, Inc. has a 1 year low of $0.53 and a 1 year high of $2.38. The business’s 50 day simple moving average is $0.81 and its 200-day simple moving average is $0.83.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.04. On average, sell-side analysts expect that Werewolf Therapeutics, Inc. will post -1.29 earnings per share for the current year.

Institutional Investors Weigh In On Werewolf Therapeutics

Hedge funds have recently modified their holdings of the business. Qube Research & Technologies Ltd purchased a new stake in Werewolf Therapeutics during the second quarter worth $48,000. Regal Investment Advisors LLC grew its stake in shares of Werewolf Therapeutics by 93.3% during the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after acquiring an additional 25,389 shares during the last quarter. Vontobel Holding Ltd. increased its stake in Werewolf Therapeutics by 66.7% during the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after purchasing an additional 24,003 shares in the last quarter. AQR Capital Management LLC acquired a new position in shares of Werewolf Therapeutics in the 1st quarter valued at $79,000. Finally, Susquehanna International Group LLP increased its holdings in shares of Werewolf Therapeutics by 16.9% in the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after purchasing an additional 13,439 shares during the period. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Wall Street Analyst Weigh In

HOWL has been the topic of several recent analyst reports. Wall Street Zen downgraded shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $3.75.

Read Our Latest Report on HOWL

Werewolf Therapeutics Company Profile

(Get Free Report)

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.